LKLingyao Kong

Lingyao Kong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lingyao Kong has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Severe attacks and worse prognosis in patients with late-onset neuromyelitis optica spectrum disorder highlight the need for early highly effective treatment

    by Rui Wang, Xiaofei Wang, Ziyan Shi, Lingyao Kong, Qin Du, Ying Zhang, Hongxi Chen, Nana Zhang, Yangyang Zhang, Hongyu Zhou

    Background and objectives Patients with late-onset neuromyelitis optica spectrum disorder (LO-NMOSD) have a worse prognosis than those with early onset NMOSD (EO-NMOSD), with limited immunotherapy data for patients with LO-NMOSD. We compared the efficacy of moderate and highly effective treatments for patients with LO-NMOSD. Methods We retrospectively included 695 aquaporin-4 immunoglobulin G-positive patients with EO-NMOSD (onset at age < 50 years) and LO-NMOSD (onset at age ≥ 50 years), comparing their clinical and immunologic features. Patients with LO-NMOSD were divided into two subgroups: one using moderately effective treatments, and one using highly effective treatments, focusing on relapse rates and prognostic outcomes. Results In total, 208 (29.9%) patients had LO-NMOSD. The median disease duration was 4.21 years for the LO-NMOSD group and 7.33 years for the EO-NMOSD group. Patients with LO-NMOSD had a higher proportion of myelitis (47.6% vs. 31.2%) and higher Expanded Disability Status Scale (EDSS) scores at first attack [false discovery rate (FDR) corrected p = 0.001]. Severe attacks (EDSS ≥ 6) and motor disability at last follow-up was less common in EO-NMOSD. No difference in visual disability was observed between the two groups at last follow-up. Among patients with LO-NMOSD, 170 (81.7%) received moderately effective treatment and 38 (18.3%) received highly effective treatment. Patients using moderately effective treatments had a lower relapse-free rate than those using highly effective treatments (67.1% vs. 94.7%). Discussion Patients with LO-NMOSD had more severe attacks and worse prognoses than those with EO-NMOSD. Patients with LO-NMOSD may choose highly effective treatments as a first-line therapy.


  • Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD

    by Rui Wang, Xiaofei Wang, Dongren Sun, Ziyan Shi, Lingyao Kong, Qin Du, Ying Zhang, Hongxi Chen, Nana Zhang, Hongyu Zhou

    Objective Serum glial fibrillary acidic protein (sGFAP) and neurofilament light chain (sNfL) levels are potential biomarkers for disease activity and disability in Neuromyelitis Optica Spectrum Disorder (NMOSD), respectively; however, their clinical applications in NMOSD remain unclear. Therefore, this study aims to investigate the correlation between sGFAP and sNfL levels and the activity, severity of attacks, disability in patients with NMOSD. Methods SGFAP and sNfL levels were measured in healthy controls (HCs) (n = 20) and patients with NMOSD (n = 86; 50 during attack and 50 in remission) using ultrasensitive single-molecule array assays. The relationships between the two biomarkers and different stages of NMOSD, the severe attacks, the Expanded Disability Status Scale (EDSS) scores, and the prognosis were analyzed. Results SNfL and sGFAP levels were significantly higher in patients with NMOSD than in HCs in the acute and remission phases (p < 0.05). The sGFAP level was higher in the acute phase than in the remission phase (P < 0.001). SNfL and sGFAP levels were higher in the severe myelitis attack group than in the severe optic neuritis attack group (p < 0.05). The EDSS ≥ 6 NMOSD group had significantly higher sNfL and sGFAP levels than the EDSS < 6 group (p < 0.05). SNfL and sGFAP levels in acute and remission stages increased with increasing EDSS scores (p < 0.05). SGFAP could discriminate patients with NMOSD with relapse from those under remission (p < 0.001). Conclusion sNfL and sGFAP may serve as biomarkers for NMOSD severity, activity, and motor disability.


  • Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder

    by Rui Wang, Dongren Sun, Xiaofei Wang, Ziyan Shi, Lingyao Kong, Qin Du, Ying Zhang, Hongxi Chen, Wenqin Luo, Nana Zhang, et al.

    Aquaporin 4-immunoglobulin G (AQP4-IgG) specifically targets aquaporin 4 in approximately 80% of Neuromyelitis Optica Spectrum Disorder (NMOSD) cases. NMOSD is presently categorized as anti-AQP4-antibody (Ab) positive or negative based on AQP4-Ab presence. The association between antibody titers and patient prognosis remains unclear. Therefore, the present study explores the correlation between severe attacks and serum AQP4 Ab titers in patients with neuromyelitis optica spectrum disorder. Data were gathered retrospectively from 546 patients with NMOSD between September 1, 2009, and December 1, 2021. Patients were categorized based on their AQP4-Ab titers: AQP4 titer ≥ 1:320 were classified as the high-titer group, AQP4 (+ +), and AQP4 titer of ≤ 1:100 were classified as the low-titer group, AQP4 ( +). Clinical characteristics and prognoses between the two groups were compared. Patients with AQP4 ( +) exhibited few severe optic neuritis (SON) attacks (false discovery rate [FDR] corrected p < 0.001), a reduced percentage experiencing SON attacks, and a lower incidence of visual disability than patients with AQP4 (+ +). Patients with AQP4 (+ +) and AQP4 ( +) NMOSD exhibited significant difference in annual recurrence rate (ARR) (FDR-corrected p < 0.001). The lower AQP4 Ab titer group demonstrated reduced susceptibility to severe relapse with conventional immunosuppressive agents and rituximab (RTX) than the higher titer group. No significant differences in sex, age at onset, coexisting connective tissue diseases, motor disability, or mortality rates were observed between the two groups. Higher AQP4 Ab titers correlated with increased disease severity and visual disability in patients with NMOSD.